The addition of fentanyl to the nation’s drug supply has dramatically escalated overdose deaths and required providers to urgently “step up” our collective efforts to treat SUD & OUD – requiring compassion, commitment, and innovation. This conference provides prescribers and their multi-professional teams the opportunity to hear from national speakers and their colleagues and explore innovative strategies to advance our treatment efforts. Join us to hear advances on the latest in practices to initiate buprenorphine and its new formulations, create contingency management programs to address stimulant use, implement peer services, partner with corrections, and more. Join your colleagues to explore how we can together step it up – it’s about saving lives.
Maple Hill Farm Inn and Conference Center | June 14, 2023 | 8:00AM- 4:00PM
CMEs and other contact hour offered. See the registration page or below for more information.
This activity includes topics recommended by the DEA and SAMHSA to satisfy 2023 MATE Act requirements. This activity qualifies for 3 credit(s) of the 3
CME credit requirement for opioid medication education found in P.L. 2015, Chapter 488, Maine’s legislation to address the opioid drug crisis.
Master of Ceremony
Buprenorphine Initiations in the World of Fentanyl
Presenter: Zoe Weinstein, MD, MS, Boston Chobanian & Advedisian School of Medicine
With the majority of the drug supply containing fentanyl, what are the strategies for high and low-dose initiations in the inpatient setting? Dr. Weinstein will explore ways to safely transition our patients onto buprenorphine, given the potential risks. She will highlight what we know and what are the directions of future research for inpatient and outpatient buprenorphine induction.
Contingency Management: Experiences with Implementation
Presenter: Marielle Baldwin, MD, MPH, Boston Chobanian & Advedisian School of Medicine
Contingency Management (CM) is an evidence-based behavioral intervention using positive reinforcements to help people change their substance use patterns. CM has shown efficacy in reducing the use of a range of substances, including stimulants (cocaine and methamphetamine), alcohol, opioids, marijuana, and nicotine. Dr. Baldwin will: examine the principles of and evidence in support of contingency management as an effective treatment for a range of substance use disorders; highlight an example of CM in the treatment of stimulant use disorders specifically; discuss the basics of CM implementation, along with challenges of implementation.
Exploring the Opioid Clinical Committee’s (Opioid CAC) Guidance Documents
Panelists: Rachel Solotaroff, MD, Alane O’Connor, DNP and Kelley Harmon, DO
An exploration of two Opioid CAC Guidance documents to guide our practices by panelists.
- Ensuring Access to Medications for Opioid Use Disorder (MOUD) in Hospital Settings
- Draft Ambulatory withdrawal and care for OUD/AUD/Other SUD
What We Do Matters: Addressing Stigma in Health Care Towards People Who Use Substances
This session will feature a documentary-style video to reveal the expressions and impact of stigma towards people with substance use disorders when they seek healthcare. A brief discussion will follow the video to promote further processing of the material presented.
Facilitator: Kristen Silvia, MD
Please review the workshop descriptions below and select one workshop from each Session (Morning and Afternoon) to attend. Once you have selected the workshops that you would like to attend, you can register for the Step it Up Conference here:
Morning Session Workshops
Workshop A1: Addiction Recovery Support Services: Rationale and Science
Presenter: John Kelly, Ph.D. (pre-recorded video) and Reflective Panel
During the past 50 years in the United States we have learned a great deal about the causes, prevalence, clinical course, and impact of alcohol and other drug use disorders, including that these disorders tend to have a long course. Even when individuals achieve initial remission, risk for recurrence of the disorder can remain elevated for several years. This presentation will provide brief contextual overview of what has been learned during the past 50 years of addiction science which has led to the emergence and growth of new models of extended recovery support services that are demonstrating effectiveness and cost-effectiveness in facilitating long-term remission and stable recovery.
Workshop B1: Partnering with Corrections
Presenters: Alane O’Connor, DNP , Melissa Caminiti, MPH, RN & Elizabeth Simoni, JD
Location: Carriage House
Come learn about substance use disorder treatment in Maine jails and prisons. Presenters will review related literature as well as their own experience of successes and challenges in delivering SUD treatment in correctional settings. Presenters will also discuss successful diversion programs including pretrial/community corrections supervision rather than detention
Workshop C1: Ambulatory Withdrawal Management and Identifying Risk for Withdrawal
Presenter: Nicholas Piotrowski, MD, FASAM
Location: Gathering Place
Many patients can receive treatment for alcohol withdrawal safely in the community with the support of a primary care provider. This program will provide an overview of key elements and safety considerations of ambulatory alcohol withdrawal management programs. Consideration also will be given to the risk of other drugs including opioids in alcohol withdrawal management.
Afternoon Session Workshops
Workshop A2: Implementing Peer Recovery as Part of the Clinical Team
Presenter: Amanda Thompson
The integration of a peer support role within SUD treatment programs can have a profound positive effect on team dynamics and patient outcomes. In this session, we’ll discuss peer support model fidelity, role clarity, and strategies to successfully integrate the role on multidisciplinary teams, including supervision and communication recommendations.
Workshop B2: Treating Adolescents with Substance Use Disorders in Maine
Presenters: Deborah Hagler, MD, Jonathan Fanburg, MD
Location: Carriage House
Join Deborah Hagler, MD, and Jonathan Fanburg, MD, as they discuss an overview of what is currently happening regarding adolescent Substance Use Disorders (SUD) screening, prevention, and treatment in Maine, things to consider as an adult provider treating adolescents, and challenges that are specific to treating adolescents with a SUD in Maine (attention will be given to treatment of adolescents using opioids). There will be time at the end to ask questions and share challenges you might be facing when it comes to treating adolescents.
Workshop C2: Enhancing Access to Extended-Release Buprenorphine for Patients with Opioid Use Disorder (Opioid CAC Guidance Doc)
Presenter: Alane O’Connor, DNP, Kristen Silvia, MD, Anne Marie Toderico, PharmD
Location: Gathering Place
Come learn how to utilize extended-release buprenorphine (XRB) when caring for patients with OUD. We will discuss clinical indications including XRB dosing and administration, XRB operational considerations including REMS certification as well as ordering, storing, and billing for the medication. Finally, we will discuss Mainecare’s XRB clinical criteria and related suggested workflows.
Additional Workshop Session Faculty
Continuing Medical Education
This activity includes topics recommended by the DEA and SAMHSA to satisfy 2023 MATE Act requirements.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Maine Medical Education Trust and CCSME. The Maine Medical Education Trust is accredited by the Maine Medical Association Committee on Continuing Medical Education and Accreditation to provide continuing medical education for physicians.
The Maine Medical Education Trust designates this live in person activity for a maximum of 6.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity qualifies for 3 credit(s) of the 3 CME credit requirement for opioid medication education found in P.L. 2015, Chapter 488, Maine’s legislation to address the opioid drug crisis.
This program constitutes 6.5 hours of training through AdCare Educational Institute of Maine, Inc. for the following credentials:
- AdCare Educational Institute is a National Association for Alcoholism and Drug Abuse Counselors (NAADAC) approved education provider. Provider #62201 6.5 Hours of Continuing Education.
- AdCare Educational Institute, Inc. is approved by the American Psychological Association to sponsor continuing education for psychologists. AdCare Educational Institute, Inc. maintains responsibility for this program and its content. 6.5 hours of continuing education. Partial credit will not be issued.
Certified Prevention Specialists: This training is approved by the Maine Prevention Certification Board and meets the requirements for Prevention Specialist Certification in Maine. 6.5 hours of training for Certified Prevention Specialists: IC&RC Prevention Performance Domains: 6:.5 Professional Growth and Responsibility.
Social Workers: The Board of Social Workers Licensure does not pre-approve continuing education. Retain a copy of certificate issued and training agenda to provide to the Maine State Board of Social Workers. Provision of these two documents is necessary for the Board of Social Workers to issue continuing education credit.
Licensed Counselors: The Maine State Board of Counseling Professionals does not pre-approve continuing education. Retain a copy of certificate issued and training agenda to provide to the Maine State Board of Counseling Professionals. Provision of these two documents is necessary for the Board of Counseling Professionals to issue continuing education credit.